Semaglutide and tirzepatide represent new treatment modalities in type 2 diabetes mellitus (T2DM) and obesity and increase the range of glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs). Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.